Jonathan Villena‐Vargas

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas et al. · Journal of Clinical Investigation · 2016 · 1.1K citations · Full text

Life Sciences, Immunology, Oncology +17

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

Prasad S. Adusumilli, Leonid Cherkassky, Jonathan Villena‐Vargas et al. · Science Translational Medicine · 2014 · 567 citations

Life Sciences, Immunology, Oncology +13

Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease

Kyuichi Kadota, Jonathan Villena‐Vargas, Akihiko Yoshizawa et al. · The American Journal of Surgical Pathology · 2014 · 253 citations · Full text

Medicine, Oncology, Pathology +17

Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma

Stefan S. Kachala, Adam J. Bograd, Jonathan Villena‐Vargas et al. · Clinical Cancer Research · 2013 · 190 citations · Full text

Medicine, Cancer Biology, Oncology +17

Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma

Kyuichi Kadota, Yi‐Chen Yeh, Jonathan Villena‐Vargas et al. · CHEST Journal · 2015 · 80 citations · Full text

Medicine, Cancer Biology, Oncology +17